The U.S. Food and Drug Administration on Friday approved Syndax Pharmaceuticals' drug for the treatment of adult and ...

Pharmaceuticals announced that the U.S. FDA has approved Revuforj as the first and only menin inhibitor for the treatment of ...

Anxious and bewildered, some drugmakers are reaching out to their lobbyists about how Robert Kennedy’s pending nomination ...

Research that was carried out by Baylor College of Medicine and Texas Children's Hospital doctors has led to the U.S. Food ...

Revuforj was approved by the FDA for adults and children with relapsed/refractory acute leukemia with a KMT2A translocation.

The Food and Drug Administration approved Revuforj from Syndax (SNDX) Pharmaceuticals, a menin inhibitor, for relapsed or refractory acute ...

The Mental Health Watchdog calls for reforms to protect public safety, citing decades of antidepressant, electroshock, and psychedelic drug risks.

The FDA has approved revumenib (Revuforj) for the treatment of adult and pediatric patients aged 1 year and older with ...

Kennedy has been most vocal about the FDA, an agency that oversees nearly $3 trillion in medicines, food and tobacco products ...

"Severe neutropenia occurs in a small percentage of patients taking clozapine; however, neutropenia is associated with an ...

Eyenovia’s stock craters to its lowest point in its six-year lifespan as a public company following the biotech’s termination ...

Robert F. Kennedy Jr., Trump's pick​ to lead the Department of Health and Human Services, has raised controversy on topics ...